首页|期刊导航|岭南现代临床外科|小细胞癌与腺癌双向转化晚期肺癌综合治疗1例报道并文献回顾

小细胞癌与腺癌双向转化晚期肺癌综合治疗1例报道并文献回顾OA

Comprehensive treatment of advanced lung cancer with bidirectional transformation between small cell carcinoma and adenocarcinoma:a case report and literature review

中文摘要英文摘要

总结1例小细胞癌(SCLC)与腺癌(ADC)双向转化的晚期肺癌患者的诊疗过程,探讨其疾病转化及多线治疗策略.分析1例右侧SCLC Ⅳ期患者的临床资料、病理特征、基因检测结果及治疗经过.患者为51岁女性,历经阿替利珠单抗联合EP方案一线治疗、贝伐珠单抗联合奥希替尼二线治疗及后续治疗.治疗过程中出现SCLC→肺腺癌(ADC)→SCLC的双向病理转化,并检出EGFR基因第19外显子突变(p.L747_P753delinsS).患者总生存期达37个月.本文展示了SCLC在治疗压力下出现病理转化和基因突变演变的复杂性,基于动态再活检的多线个体化治疗可为晚期患者带来生存获益,旨在为临床实践提供参考.

This report aimed to summarize the diagnosis and treatment process of a patient with advanced lung cancer with bidirectional transformation between small cell lung carcinoma and lung adenocarcinoma and to explore the disease transformation and multi-line treatment strategies.The clinical data,pathological features,genetic testing results,and treatment course of a patient with stage Ⅳ right-sided SCLC were analyzed.The patient was a 51-year-old woman who received first-line therapy with atezolizumab plus EP regimen,second-line therapy with bevacizumab plus osimertinib,and multiple subsequent lines of treatment.During the treatment course,bidirectional pathological transformation(SCLC → lung adenocarcinoma → SCLC)occurred,and an EGFR exon 19 mutation(p.L747_P753de-linsS)was detected.The patient's overall survival reached 37 months.This case demonstrates the com-plexity of pathological transformation and genetic mutation evolution in SCLC under therapeutic pres-sure.Multi-line individualized therapy based on dynamic re-biopsy can provide survival benefits for patients with advanced SCLC.This report aims to provide a reference for clinical practice.

乐灵丹;谢德荣;江志敏

中山大学孙逸仙纪念医院肿瘤内科,广州 510120中山大学孙逸仙纪念医院肿瘤内科,广州 510120中山大学孙逸仙纪念医院肿瘤内科,广州 510120

医药卫生

小细胞肺癌肺腺癌病理转化EGFR突变多线治疗病例报道

small cell lung cancerlung adenocarcinomapathological transformationEGFR muta-tionmulti-line treatmentcase report

《岭南现代临床外科》 2026 (4)

273-279,7

10.3969/j.issn.1009-976X.2026.04.010

评论